{
    "2018-06-21": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study",
                "features": {
                    "keywords": [
                        "Nordisk",
                        "Oral Ozempic",
                        "Diabetes Study",
                        "Positive"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-16",
                "original_text": "Novo Nordisk Stock Rises 4% Over 2 Sessions",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Stock Rises",
                        "4%",
                        "Sessions"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-17",
                "original_text": "Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Oral Ozempic",
                        "Diabetes Study",
                        "Positive"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-18",
                "original_text": "European ADRs Move Lower in Thursday Trading",
                "features": {
                    "keywords": [
                        "European ADRs",
                        "Move Lower",
                        "Thursday Trading"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance",
                        "international markets"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-03-19",
                "original_text": "Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Stock Pops",
                        "3%",
                        "Diabetes-Drug Results",
                        "Positive"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-20",
                "original_text": "Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Kallyope",
                        "Obesity",
                        "Diabetes Drugs",
                        "Deal"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}